GBT Announces Participation in Upcoming Investor Conferences
September 02 2021 - 8:00AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today
announced that it will participate in virtual fireside chats at the
following investor conferences:
- 2021 Wells Fargo Virtual Healthcare
Conference on September 10 at 1:20 p.m. ET; and
- Morgan Stanley 19th Annual Global Healthcare Conference on
September 13 at 12:30 p.m. ET.
The fireside chats will be webcast live from
GBT’s website at www.gbt.com in the Investors section. Replays of
the webcasts will be archived and available for one month following
each event.
About Global Blood
Therapeutics
Global Blood Therapeutics (GBT) is a
biopharmaceutical company dedicated to the discovery, development
and delivery of life-changing treatments that provide hope to
underserved patient communities. Founded in 2011, GBT is delivering
on its goal to transform the treatment and care of sickle cell
disease (SCD), a lifelong, devastating inherited blood disorder.
The company has introduced Oxbryta® (voxelotor) tablets, the
first FDA-approved treatment that directly inhibits sickle
hemoglobin polymerization, the root cause of red blood cell
sickling in SCD. GBT is also advancing its pipeline program in SCD
with inclacumab, a P-selectin inhibitor in Phase 3 development to
address pain crises associated with the disease, and GBT021601
(GBT601), the company’s next-generation hemoglobin S polymerization
inhibitor. In addition, GBT’s drug discovery teams are working on
new targets to develop the next wave of potential treatments for
SCD. To learn more, please visit www.gbt.com and follow the
company on Twitter @GBT_news.
Contact:Steven Immergut
(media)650-410-3258simmergut@gbt.com
Courtney
Roberts (investors)650-351-7881croberts@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Apr 2023 to Apr 2024